Tocagen Inc

Tocagen — Forte Biosciences — Investor Presentation (March 2021)

30 slides from Tocagen's investor presentation, Mar 24, 2021

  1. Slide 1: Forte Biosciences Corporate Presentation March 2021

    FORTE BIOSCIENCES TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION MARCH 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These i

  3. Slide 3: Summary of Forte Biosciences: FB-401

    SUMMARY OF FORTE BIOSCIENCES: FB-401 – POTENTIAL FIRST-IN-CLASS TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE 3 LATE-STAGE CLINICAL ASSET Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well tolerated and demonstrated clin

  4. Slide 4: Forte Biosciences: Overview of FB-401

    FORTE BIOSCIENCES:OVERVIEW OF FB-401 4 FB-401 drug product consists of 3 therapeutic bacterial strains of commensal Gram-negative R. mucosa specifically selected based on screening for impact on inflammatory skin disease parameters Topical application of the specifically selected therapeutic bacteri

  5. Slide 5: Experienced Management and Advisory Teams

    5 EXPERIENCED MANAGEMENT AND ADVISORY TEAMS Paul Wagner, Ph.D. – CEO Forte BioSciences team has extensive experience in microbial manufacturing, quality, regulatory and clinical development in dermatology Dan Burge, MD – Head of Clinical Development Eric Emery – Head of Downstream Manufacturing Hank

  6. Slide 6: Atopic Dermatitis

    ATOPIC DERMATITIS Atopic dermatitis (AD) is characterized by itching, a scaly rash, dry skin, and cutaneous sensitization to allergens. The underlying pathology of AD consists of a triad of defective skin barrier function, susceptibility to Staphylococcus aureus skin infection, and immune imbalance

  7. Slide 7: Skin Microbiome

    SKIN MICROBIOME Recent work has revealed that the skin microbiome is significantly different between healthy controls and patients with AD and that symptoms are associated with a loss of commensal diversity Dreno et al, European Academy of Dermatology and Venerology 2016, 30, 2038-2047 Kong HH et al

  8. Slide 8: Skin Microbiome Differences in Atopic Dermatitis

    SKIN MICROBIOME DIFFERENCES IN ATOPIC DERMATITIS Myles IA,Williams KW, Reckhow JD, et al. JCI Insight. 2016;1(10) Kong HH et al. Genome research. 2012;22(5):850-859 8 Genetic-based microbiome identification revealed significant differences in the Gram-negative skin biome between atopic dermatitis (A

  9. Slide 9: Mechanism of FB-401

    MECHANISM OF FB-401 CONFIDENTIAL 9 Extensive preclinical work by Forte in collaboration with NIH, investigating the activity of FB-401 has demonstrated: FB-401 activates tissue repair and anti-inflammation pathways in keratinocytes, dendritic cells and fibroblasts Gene sequencing of the FB-401 strai

  10. Slide 10: Multiplex Gene Pathway Analysis: FB-401 Activates Tissue Repair/Anti-Inflammation Pathways

    L MULTIPLEX GENE PATHWAY ANALYSIS (RNASEQ): FB-401 ACTIVATES TISSUE REPAIR/ANTI-INFLAMMATION PATHWAYS Gene FB ESC KC DC Fibroblast, keratinocyte, embryonic stem cell and dendritic cell demonstrate tissue repair pathway activation following exposure to FB-401 including TLR5, TNFR and CXCR2 driving ep

  11. Slide 11: Scratch Models Confirm Tissue Repair Through TLR5 Pathway Activation

    FIBROBLAST AND KERATINOCYTE SCRATCH MODELS CONFIRM TISSUE REPAIR THROUGH TLR5 PATHWAY ACTIVATION BY FB-401 CONFIDENTIAL FB Coverage PBS RmHV KC Coverage Scratch model for both keratinocytes and fibroblasts demonstrates tissue repair by FB-401 Blocking TLR5 (anti-TLR5 antibody) prevents tissue repair

  12. Slide 12: TNFR Knock Out Mouse Models Confirm Response Dependent on TNFR Signaling

    TNFR KNOCK OUT MOUSE MODELS CONFIRMS RESPONSE TO FB- 401 IS DEPENDENT ON TNFR SIGNALING CONFIDENTIAL 12 TNFR wild type mice demonstrate atopic dermatitis activity of FB-401 TNFR knockout inhibits FB-401 activity Myles IA et al. Science Translational Medicine. 2020; 12

  13. Slide 13: CXCR2 Knock Out Mouse Model Shows Response Dependent on IL-8 Signaling

    CXCR2 KNOCK OUT MOUSE MODEL DEMONSTRATES RESPONSE TO FB-401 IS DEPENDENT ON IL-8 SIGNALING CONFIDENTIAL 13 CXCR2 wild type mice demonstrate atopic dermatitis activity of FB-401 CXCR2 knockout inhibits FB-401 activity

  14. Slide 14: Phase 2a First Human Study of FB-401

    PHASE 2A FIRST HUMAN STUDY OF FB-401 - CUTANEOUS LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF ATOPIC DERMATITIS Drug product: FB-401 (3 specifically selected therapeutic R. mucosa strains) lyophilized and reconstituted with sterile water in single-use, self-administered spray Design: Phase 1/2a enrolled

  15. Slide 15: Cohort Completed Treatment of Adults with AD

    COHORT 1 COMPLETED TREATMENT OF 10 ADULTS WITH AD Ten adult AD patients ages 18 years and older were treated in 2-week intervals with 103, 104, and then 105 CFU of R mucosa twice per week (BIW) for a total of 6 weeks 15

  16. Slide 16: Statistically Significant, Dose-Dependent Improvements in Adult Cohort

    STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT IMPROVEMENTS OBSERVED IN ADULT COHORT OF PHASE 1/2a STUDY (A) Intensity of AD disease was measured in a blinded manner using SCORAD measures of dryness, redness, lichenification, excoriation, crusting and edema (0-3 scale for each measure) (B) Subjective pru

  17. Slide 17: Cohort 2: FB-401 Treatment of Children with AD

    COHORT 2: FB-401 TREATMENT OF 20 CHILDREN WITH AD 17 20 pediatric/adolescent patients with active AD: First 5, ages 7-17 Remainder, ages 3-17 Baseline SCORAD >10 Design: Treat AD-involved skin with FB-401 103 CFU BIW for 4 weeks 104 CFU BIW for 4 weeks 105 CFU BIW for 4 weeks 105 CFU QOD for 4 weeks

  18. Slide 18: Pediatric Patient Data Shows Significant Activity

    PEDIATRIC PATIENT DATA SHOWS SIGNIFICANT ACTIVITY – TREATMENT THROUGH W16, FOLLOW UP 6 M AFTER TREATMENT COMPLETION CONFIDENTIAL 18 N Ave baseline SCORAD Responder % All Responders SCORAD (50% improvement) 20 36.1 17 85.0% 65.6% 73.2% Average Response * p<0.05 ** P<0.01 *** p<0.001 **** p<0.0001 Dot

  19. Slide 19: Pruritus (Itch) Significantly Improved Over Course of Therapy

    PRURITIS (ITCH) SIGNIFICANTLY IMPROVED OVER COURSE OF THERAPY CONFIDENTIAL 19 Pruritus Measures Part 2A N=15 Part 2B N=5 Total N=20 Mean baseline pruritus score 6.4 7.1 6.6 Mean Week 16 pruritus score 2.3 3.4 2.6 Mean % improvement 59.7% 51.0% 57.6% Myles IA et al. Science Translational Medicine. 20

  20. Slide 20: Pediatric Patient EASI Efficacy Data Shows Significant Activity

    PEDIATRIC PATIENT EASI EFFICACY DATA SHOWS SIGNIFICANT ACTIVITY CONFIDENTIAL 20 EASI Severity Mild<7 Moderate 7-21 Severe>21 Ave baseline N EASI Responders % EASI-50 20 7.8 18 90.0% N Ave baseline EASI Responders % EASI-75 20 7.8 14 70.0% All 76.8% Responders 83.6% N Ave baseline EASI 7.8 Responders

  21. Slide 21: Pediatric Efficacy Data Across Disease Severity

    PEDIATRIC PATIENT EFFICACY DATA SHOWS SIGNIFICANT ACTIVITY ACROSS DISEASE SEVERITY CONFIDENTIAL 21 Mild Disease EASI=<7 at baseline N=11 Moderate/Severe Disease EASI>=7 at baseline N=9 Trial Protocol EASI =>5 at baseline N=14 Total N=20 EASI 50 81.8% (9/11) 100% (9/9) 100% (14/14) 90% (18/20) EASI 7

  22. Slide 22: Treatment with FB-401 Demonstrates Significant Improvement

    TREATMENT WITH FB-401 DEMONSTRATES SIGNIFICANT IMPROVEMENT 22 Myles et al, JCI Insight, 2018;3(9):e120608

  23. Slide 23: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY CONFIDENTIAL 23 Week 0Week 16 Myles IA et al. Science Translational Medicine. 2020; 12

  24. Slide 24: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY CONFIDENTIAL 24 Week 0 Week 16

  25. Slide 25: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY NTIAL 25 CONFIDE Week 0Week 16 Myles IA et al. Science Translational Medicine. 2020; 12

  26. Slide 26: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY CONFIDENTIAL 26 Week 0 Week 16 Myles IA et al. Science Translational Medicine. 2020; 12

  27. Slide 27: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY 27 CONFIDENTIAL

  28. Slide 28: Planned FB-401 Randomized Phase 2 Study

    PLANNED FB-401 RANDOMIZED PHASE 2 STUDY CONFIDENTIAL 28 Randomized, placebo-controlled, multi-center study Includes children (2 years and older), adolescents and adults with mild to moderate atopic dermatitis Subjects randomized 1:1 to receive FB-401 or placebo for 16 weeks Endpoints include Eczema

  29. Slide 29: Intellectual Property Overview

    INTELLECTUAL PROPERTY OVERVIEW Exclusive license to NIH-owned patent family focused on treatment of AD with a consortia of Gram- negative bacteria from healthy donors Patent coverage through at least 2037 9 US patents issued Entered in >15 Ex-US jurisdictions Company-owned IP directed to composition

  30. Slide 30: Summary of Forte Biosciences: FB-401

    SUMMARY OF FORTE BIOSCIENCES: FB-401 – POTENTIAL FIRST-IN-CLASS TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE 30 LATE-STAGE CLINICAL ASSET Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well tolerated and demonstrated cli

Forte Biosciences — Investor Presentation (March 2021) on 6ix